Arbutus Biopharma Corporation (ABUS)Healthcare | Biotechnology | Warminster, United States | NasdaqGS
4.60 USD
-0.12
(-2.542%) ⇩
(April 20, 2026, 4 p.m.
EDT)
Short-term: ★★★★☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 19, 2026, 1:18 a.m. EDT
Arbutus Biopharma is exhibiting a deceptive technical setup: a massive recent surge in shares that has reset the 4.67-4.72 level as resistance, but with clear call buying at the $5.00 strike signaling a test is imminent. While the long-term fundamentals are dire (revenue contraction of -33%, massive losses, and a biotech patent revocation headline), the speculative narrative is currently driven by the Moderna settlement link and the 'fast track' approval. For active traders, the $5.00 strike is the only area of conviction; for long-term holders, this is a warning signal to reduce exposure given the deteriorating cash flow and lack of a clear path to profitability, despite the high 'strong buy' analyst rating which often lags on biotech tolls. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.048254 |
| AutoARIMA | 0.062392 |
| AutoETS | 0.062393 |
| MSTL | 0.071112 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 79% |
| H-stat | 0.84 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.270 |
| Excess Kurtosis | 0.71 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 5.469 |
| Revenue per Share | 0.074 |
| Market Cap | 905,922,496 |
| Forward P/E | -27.83 |
| Beta | 0.74 |
| Profit Margins | -237.88% |
| Website | https://www.arbutusbio.com |
As of April 19, 2026, 1:18 a.m. EDT: Short-term call data shows heavy positioning at the $5.00 and $6.00 strikes for the immediate April expiration, suggesting a breakout bid if the stock holds above $4.50. Long-dated calls (2027) show significant flow into the $4.00 and $5.50 strikes, indicating a range-bound expectation with upside potential. Conversely, short-term put data reveals massive open interest (OI) in the money and slightly out of the money for the June 18 expiration, likely representing a hedging strategy by shareholders or a 'pinners' defense against moves below current levels. The net sentiment is bullish regarding the $5.00 breakout target, but captrading is evident.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.44200623 |
| Address1 | 701 Veterans Circle |
| All Time High | 31.48 |
| All Time Low | 0.82 |
| Ask | 4.64 |
| Ask Size | 17 |
| Audit Risk | 3 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 1,752,960 |
| Average Daily Volume3 Month | 2,185,632 |
| Average Volume | 2,185,632 |
| Average Volume10Days | 1,752,960 |
| Beta | 0.738 |
| Bid | 4.58 |
| Bid Size | 17 |
| Board Risk | 7 |
| Book Value | 0.398 |
| City | Warminster |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 7 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 4.6 |
| Current Ratio | 15.727 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 4.71 |
| Day Low | 4.595 |
| Debt To Equity | 5.469 |
| Display Name | Arbutus Biopharma |
| Earnings Call Timestamp End | 1,730,900,700 |
| Earnings Call Timestamp Start | 1,730,900,700 |
| Earnings Timestamp | 1,774,269,000 |
| Earnings Timestamp End | 1,778,675,400 |
| Earnings Timestamp Start | 1,778,675,400 |
| Ebitda | -26,688,000 |
| Ebitda Margins | -1.89505 |
| Enterprise To Ebitda | -30.423 |
| Enterprise To Revenue | 57.652 |
| Enterprise Value | 811,916,096 |
| Eps Current Year | -0.227 |
| Eps Forward | -0.16528323 |
| Eps Trailing Twelve Months | -0.17 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 4.4044 |
| Fifty Day Average Change | 0.19560003 |
| Fifty Day Average Change Percent | 0.044410143 |
| Fifty Two Week Change Percent | 44.200623 |
| Fifty Two Week High | 5.1 |
| Fifty Two Week High Change | -0.5 |
| Fifty Two Week High Change Percent | -0.09803922 |
| Fifty Two Week Low | 2.94 |
| Fifty Two Week Low Change | 1.6599998 |
| Fifty Two Week Low Change Percent | 0.5646258 |
| Fifty Two Week Range | 2.94 - 5.1 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,185,456,600,000 |
| Float Shares | 125,233,024 |
| Forward Eps | -0.16528323 |
| Forward P E | -27.831013 |
| Free Cashflow | -17,619,500 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 19 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | -0.79230005 |
| Gross Profits | -11,158,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.20521 |
| Held Percent Institutions | 0.64308 |
| Implied Shares Outstanding | 196,939,679 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,288,828,800 |
| Last Split Factor | 1:5 |
| Long Business Summary | Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania. |
| Long Name | Arbutus Biopharma Corporation |
| Market | us_market |
| Market Cap | 905,922,496 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_34160168 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -33,501,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 905,922,523 |
| Number Of Analyst Opinions | 3 |
| Open | 4.7 |
| Operating Cashflow | -39,637,000 |
| Operating Margins | -7.27307 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 267 469 0914 |
| Pre Market Change | 0.06710005 |
| Pre Market Change Percent | 1.4586967 |
| Pre Market Price | 4.6671 |
| Pre Market Time | 1,776,770,304 |
| Previous Close | 4.72 |
| Price Eps Current Year | -20.264317 |
| Price Hint | 4 |
| Price To Book | 11.557789 |
| Price To Sales Trailing12 Months | 64.32738 |
| Profit Margins | -2.37883 |
| Quick Ratio | 15.521 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.33333 |
| Region | US |
| Regular Market Change | -0.12 |
| Regular Market Change Percent | -2.54237 |
| Regular Market Day High | 4.71 |
| Regular Market Day Low | 4.595 |
| Regular Market Day Range | 4.595 - 4.71 |
| Regular Market Open | 4.7 |
| Regular Market Previous Close | 4.72 |
| Regular Market Price | 4.6 |
| Regular Market Time | 1,776,715,201 |
| Regular Market Volume | 873,163 |
| Return On Assets | -0.1494 |
| Return On Equity | -0.3852 |
| Revenue Growth | -0.332 |
| Revenue Per Share | 0.074 |
| Sand P52 Week Change | 0.34445214 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 9 |
| Shares Outstanding | 196,939,679 |
| Shares Percent Shares Out | 0.082100004 |
| Shares Short | 16,174,093 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 14,756,509 |
| Short Name | Arbutus Biopharma Corporation |
| Short Percent Of Float | 0.1224 |
| Short Ratio | 5.56 |
| Source Interval | 15 |
| State | PA |
| Symbol | ABUS |
| Target High Price | 5.6053553 |
| Target Low Price | 5.0041018 |
| Target Mean Price | 5.2272243 |
| Target Median Price | 5.0722094 |
| Total Cash | 91,471,000 |
| Total Cash Per Share | 0.468 |
| Total Debt | 4,188,000 |
| Total Revenue | 14,083,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.17 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 4.20575 |
| Two Hundred Day Average Change | 0.39424992 |
| Two Hundred Day Average Change Percent | 0.093740694 |
| Type Disp | Equity |
| Volume | 873,163 |
| Website | https://www.arbutusbio.com |
| Zip | 18,974 |